Oncology

Oncology Expert Witness

Oncology expert witnesses address cases involving delayed cancer diagnosis, inappropriate treatment selection, chemotherapy dosing errors, and failures in cancer surveillance that allowed preventable disease progression. Cancer cases are uniquely urgent because delays measured in weeks or months can shift a patient from a curable stage to an incurable one, with survival data providing concrete evidence of the harm caused. Attorneys need oncologists who can evaluate staging accuracy, treatment protocol selection, tumor board decision-making, and whether a diagnostic or treatment delay measurably changed the patient's prognosis.

When a patient with a suspicious breast mass undergoes imaging that recommends biopsy but the biopsy is never performed, and the patient is diagnosed with metastatic breast cancer a year later, an oncology expert can quantify the difference in five-year survival between the stage at which the cancer could have been diagnosed and the stage at which it was actually found. In cases where a patient receives the wrong chemotherapy regimen — either an incorrect drug, an inappropriate dose, or a protocol not supported by NCCN guidelines for their specific cancer type and staging — the expert evaluates whether the treatment decision deviated from the standard of care and whether the suboptimal therapy contributed to disease progression. For patients undergoing cancer treatment who develop febrile neutropenia and are not managed with emergent antibiotics and colony-stimulating factor support, the expert assesses whether the oncology team's response met the standard for managing this life-threatening complication. In cases involving failure to perform recommended surveillance after curative-intent treatment, the expert evaluates whether recurrence could have been detected and treated at an earlier, more treatable stage. For damages testimony, the oncology expert projects the long-term consequences of delayed cancer diagnosis and treatment errors — including stage-dependent survival analysis quantifying years of life lost, lifetime surveillance and follow-up costs for patients living with advanced cancer, chemotherapy-induced permanent peripheral neuropathy affecting function and employability, and secondary malignancy risk from radiation and chemotherapy requiring extended monitoring — quantifying future oncology visits, imaging surveillance, targeted therapy costs, supportive care medications, and palliative care needs across the patient's projected survival.

An oncology expert witness evaluates diagnostic and treatment decisions across the spectrum of solid tumors and hematologic malignancies: breast, lung, colorectal, prostate, ovarian, pancreatic, bladder, and renal cancers, as well as melanoma, sarcoma, and lymphoma. The expert reviews pathology reports including histologic grade and molecular markers, staging imaging, genomic testing results, tumor board documentation, NCCN guideline concordance, chemotherapy orders with dose calculations based on body surface area, radiation therapy records, and surveillance imaging timelines. They assess whether the treatment plan was individualized to the patient's cancer biology and comorbidities, whether clinical trial options were discussed when appropriate, and whether complications of treatment — including neutropenic sepsis, chemotherapy extravasation, and immune-related adverse events from checkpoint inhibitors — were managed according to established protocols. For delayed diagnosis cases, the expert provides stage-migration analysis using cancer registry survival data. Anchor connects attorneys with board-certified oncologists who subspecialize in the tumor type at issue. The oncology expert also evaluates long-term damages: stage-migration survival analysis using SEER data to quantify lost life expectancy, lifetime cancer surveillance costs including serial imaging, tumor markers, and specialist visits, chemotherapy-induced permanent peripheral neuropathy and cardiotoxicity affecting long-term function, and secondary malignancy risk from prior radiation and chemotherapy requiring extended screening. The expert projects future targeted therapy and immunotherapy costs, supportive care including antiemetics and growth factors, palliative care needs, and permanent disability from treatment sequelae for life care planning.